Table 3.

Composite and individual symptom scores over 12 weeks: longitudinal analysis of reduction from baseline in arbitrary AUC (area under the curve relative to baseline expressed as positive values) units. (Pbo = placebo)

Symptom	Mean + SD	Placebo, N=88	10 μg RM, N=86	30 μg RM, N=91	100 μg RM, N=63
4-Symptom Composite		318.1 ±546.9	501.0 ±402.4	544.0 ±577.5	554.3 ±541.4
	LS Mean Δ from Pbo		183.51	231.77	209.48
	95% CI of difference		24.11; 342.92	74.58; 388.96	35.68; 383.27
	P-value		0.02	<0.01	<0.02
Nausea		94.9 ±161.2	128.0 ±145.6	149.9 ±157.8	152.0 ±157.6
	LS Mean Δ from Pbo		34.32	57.01	50.38
	95% CI of difference		−9.19; 77.83	14.11; 99.92	2.98; 97.77
	P-value		0.12	<0.01	0.04
Post-prandial Fullness		67.3 ±139.9	118.2 ±142.0	124.1 ±150.3	126.7 ±143.9
	LS Mean Δ from Pbo		53.72	57.28	54.44
	95% CI of difference		11.64 ; 95.80	15.81; 98.75	8.60; 100.29
	P-value		<0.01	<0.01	0.02
Abdominal Pain		81.7 ±148.3	127.4 ±141.1	133.3 ±151.9	145.2 ±140.1
	LS Mean Δ from Pbo		43.09	54.42	56.47
	95% CI of difference		1.18 ; 84.99	13.09; 95.74	10.79; 102.15
	P-value		0.04	<0.01	0.02
Bloating		74.2 ±148.4	127.4 ±139.0	136.6 ±150.0	130.3 ± 142.5
	LS Mean Δ from Pbo		52.18	63.21	48.39
	95% CI of difference		10.51; 93.86	22.12; 104.31	2.94; 93.84
	P-value		<0.01	<0.01	0.04